Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 6
2020 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Citations

6 articles found by citation matching

Search results

Filters applied: . Clear all
Page 1
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Kosiborod M, et al. Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18. Circulation. 2017. PMID: 28522450 Free PMC article. Clinical Trial.
BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabete …
BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with th …
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540325 Free article. Clinical Trial.
BACKGROUND: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real- …
BACKGROUND: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose
Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847. Circulation. 2018. PMID: 29483180 No abstract available.
Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study.
Kohsaka S, Takeda M, Bodegård J, Thuresson M, Kosiborod M, Yajima T, Wittbrodt E, Fenici P. Kohsaka S, et al. J Diabetes Investig. 2021 Jan;12(1):67-73. doi: 10.1111/jdi.13321. Epub 2020 Jul 26. J Diabetes Investig. 2021. PMID: 32530554 Free PMC article.
We investigated the cardiovascular outcomes in Japanese patients with type 2 diabetes initiating sodium-glucose cotransporter 2 inhibitors (SGLT2i) matched 1:1 to patients initiating other glucose-lowering
We investigated the cardiovascular outcomes in Japanese patients with type 2 diabetes initiating sodium-glucose
Can we go beyond surrogates?
Drexler A. Drexler A. J Diabetes. 2017 Nov;9(11):976-977. doi: 10.1111/1753-0407.12583. J Diabetes. 2017. PMID: 28692750
Both studies showed a lower likelihood of hospitalization for heart failure with the intervention, even in patients without known heart failure at baseline, suggesting either that that diagnosis is often missed or that de novo heart
Both studies showed a lower likelihood of hospitalization for heart failure with the intervention, even in patients
Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation.
Kwon O, Myong JP, Lee Y, Choi YJ, Yi JE, Seo SM, Jang SW, Kim PJ, Lee JM. Kwon O, et al. J Am Heart Assoc. 2023 Jul 18;12(14):e027824. doi: 10.1161/JAHA.122.027824. Epub 2023 Jul 8. J Am Heart Assoc. 2023. PMID: 37421263 Free PMC article.
Patients given SGLT2 inhibitors or other glucose-lowering drugs were matched based on a propensity score. ...Conclusions The early use of SGLT2 inhibitors in patients with diabetes treated with percutaneous coronary intervention fo
Patients given SGLT2 inhibitors or other glucose-lowering drugs were matched based on a propensity score.
11 results